Top in ID: Protective effect of prior SARS-CoV-2 infection, FDA approval of HIV regimen

Patients who were infected with SARS-CoV-2 were protected against symptomatic reinfection with SARS-CoV-2 variants, including omicron, according to a recent study. It was the top story in infectious disease last week.

The second top story was about a recent approval from the FDA for a 2-month dosing regimen of Cabenuva — a combination of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen Pharmaceuticals) — for virologically suppressed adults with HIV.

Read these and more top stories in infectious disease below:

Prior infection protects against variants, including omicron, study finds

Prior SARS-CoV-2 infection protects against symptomatic reinfection with SARS-CoV-2 variants, including omicron, national data from Qatar showed. Read more.

FDA approves 2-month dosing of injectable, long-acting HIV treatment

Virologically suppressed adults can now receive HIV treatment as few as six times per year. Read more.

CDC adds omicron subvariant BA.2 to online tracker

The CDC has begun reporting the proportion of COVID-19 cases in the United States that are caused by the omicron subvariant BA.2. Read more.

Discovery of ‘highly virulent’ HIV variant ‘not a public health crisis’

Researchers discovered what they described as a “highly virulent” variant of HIV-1 that has been circulating in the Netherlands for the past 2 decades. Read more.

COVID-19 boosters wane over time but remain protective, study finds

The effectiveness of a COVID-19 booster shot waned over time, but the extra dose continued to protect against hospitalization at 4 months and beyond, according to data collected during the omicron surge and reported in MMWR. Read more.